However, toxicities attributed to a syndrome of secondary mineralocorticoid excess have been observed with abiraterone, and coadministration of a mineralocorticoid receptor antagonist or glucocorticoid is required to suppress adrenocorticotropic hormone (ACTH) levels [12]. The gene discussed is POMC; the disease is Increased circulating aldosterone concentration.